AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 91 min read$GKOS

Thurman Alex R. sold $1.5M of GKOS

Thurman Alex R. (SVP & CHIEF FINANCIAL OFFICER) sold 10,000 shares of GLAUKOS Corp (GKOS) at $150.00 ($1.50M total) on 2026-07-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Thurman Alex R.
Published Jul 9, 2026, 1:13 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 9, 2026, 1:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$GKOS
Neutral
high confidence
Mentioned
$GKOS
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GKOSNeutralLow
01

Why it matters

The newest fact is the disclosed sale size ($1.5M) and the fact it was executed under a pre-arranged 10b5-1 plan; this typically reduces interpretive weight.

02

Market read

Traders may note the insider sale for sentiment monitoring, but it is unlikely to drive a fundamental repricing without additional company news.

03

What to watch

The filing does not include any accompanying narrative, earnings context, or changes to corporate outlook, so traders should avoid over-weighting it versus fundamentals.

Relevance 5/10Novelty 3/10Timing: latest SEC Form 4 filed 2026-07-08 for a 2026-07-06 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Glaukos Corp, listing the CFO as the reporting insider.

Company-level read

Ticker impact

$GKOSNeutralHigh confidence
Context

Form 4 shows GKOS CFO Thurman Alex sold 10,000 shares at $150 on 2026-07-06 under a 10b5-1 plan, worth $1.5M.

Expected impact

Likely limited near-term price impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a routine insider transaction with explicit 10b5-1 pre-arrangement, and it does not disclose new company fundamentals or guidance.

Market effects

Sector

No sector read-across; this is company-specific insider dealing.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than a bearish view on GKOS.

Key entities

  • issuer
    GLAUKOS Corp

    Company whose insider transaction is disclosed on Form 4.

  • insider
    Thurman Alex R.

    SVP and Chief Financial Officer who sold 10,000 shares.

Read at source← All news

Related articles

AUG 8
$GKOSMedAI 8/10

Glaukos (GKOS) Q2 2026 Earnings Call Transcript

Glaukos (NYSE: GKOS) reported Q2 2026 net sales of $185.6 million, up 50% year over year. U.S. glaucoma sales were $118.5 million, and iDose TR revenue was about $74 million. The company raised full-year 2026 net sales guidance to $680 million to $700 million and iDose TR revenue guidance to $275 million to $280 million.

aol.com7 min
JUL 30
$GKOSHighAI 9/10

Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up

Glaukos (GKOS) reported Q2 2026 adjusted loss of 14 cents per share, better than the Zacks Consensus loss of 28 cents. Revenue rose to $185.6 million, up 50% year over year, beating the consensus by 24.1%. Management raised 2026 net sales guidance to $680 million to $700 million. Shares rose 9.8% in after-hours.

tradingview.com6 min
JUL 30
$GKOSMed

Glaukos Q2 Earnings Call Highlights

Glaukos (NYSE:GKOS) reported Q2 updates on iDose TR, including acceleration across Medicare Administrative Contractor regions and no material demand pull-forward from proposed LCDs. International glaucoma revenue rose to $36.6M (+17%); corneal health revenue rose 48% to $30.4M with ~$11M Epioxa. Gross margin was ~85%. Full-year targets: gross margin 84% to 86%, corneal health growth ~20%.

finance.yahoo.com4 min
JUL 29
$GKOSMedAI 8/10

GLAUKOS Corp (GKOS): Results of Operations and Financial Condition

GLAUKOS Corp (GKOS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 gkos-ex99_2.htm EX-99.2 EX-99.2 Exhibit 99.2 JULY 29, 2026 GLAUKOS CORPORATION (NYSE: GKOS) SECOND QUARTER 2026 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designe

SEC EDGAR 8-K6 min
JUL 29
$GKOSMed

Midday Stock Roundup: Glaukos Rises

A midday roundup highlights multiple movers. V.F. Corp. (VFC) fell 17% to $15.24 after lower first-quarter revenue tied to weakness in Vans and CFO Paul Vogel leaving. Envista (NVST) rose 6.2% to $28.63 ahead of an Sept. 17 investor day. Glaukos (GKOS) gained 7.9% to $159.25 after completing patient enrollment in a 510(k) glaucoma study.

ocbj.com3 min